UCD Researchers have identified a potential biomarker of rapidly progressing idiopathic pulmonary fibrosis and have pinpointed a defective molecular function as a potential therapeutic target. The research, published in the American Journal of Respiratory and Critical Care Medicine, was conducted at UCD Conway Institute and was supported by funding from the Health Research Board and the Irish Lung Foundation.